- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02533765
Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a proof-of principle open-label, single-arm, two-stage phase II trial of olaparib 300 mg twice daily in patients with relapsed/refractory metastatic germ cell cancer. The study will recruit 10 patients, if no response is seen the study is terminated. If one or more responses are observed, further 19 patients (for a total of 29 patients) will be enrolled. If 4 or more of the first 29 evaluable patients have achieved objective response, further studies in patients with metastatic germ cell cancer are warranted.
The main inclusion criteria are:
- Patient with metastatic gonadal GCT or extragonadal GCT originating from retroperitoneum or mediastinum.
- Disease progression during cisplatin-based chemotherapy or disease progression or relapse after high-dose chemotherapy or disease progression or relapse after at least 2 different cisplatin-based regimens
- At least one measurable lesion that can be accurately assessed by CT/MRI/plain x-ray) at baseline and follow up visits.
The study will be analyzed on an intent-to-treat basis. Secondary parameters will be analyzed exploratively for the intent-to-treat population.
Correlations between with biomarkers (PAR, poly adenosine diphosphate-ribose polymerase (PARP-1), PTEN, XPA, ERCC1-3, XPF, FanD2, γ-H2AX) expression in paraffin-embedded tumor samples and clinical outcome will be performed in an exploratory intent. Plasma samples will be collected at baseline and at response/progression for possible retrospective biomarkers study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Napoli, Italy, 80131
- Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale"
-
-
FC
-
Meldola, FC, Italy, 47014
- U.O Oncologia Medica, IRST IRCCS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients ≥ 18 years old
- Histologically verified metastatic gonadal GCT or extragonadal GCT originating from retroperitoneum or mediastinum.
- Disease progression during cisplatin-based chemotherapy or disease progression or relapse after high-dose chemotherapy or disease progression or relapse after at least 2 different cisplatin-based regimens
- patients who progressed during cisplatin-based therapy and who are not eligible for high-dose chemotherapy
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0-2
- Life expectancy ≥3 months
At baseline adequate function of liver, kidneys and bone marrow
- Neutrophils ≥ 1500 /mm3;
- Hemoglobin ≥ 9.0 g/dL;
- Platelets ≥ 80 x109/L;
- Creatinine ≤ 1.5x upper limit of normal (ULN) In case of liver metastases increased levels of the following three parameters is acceptable:
- Bilirubin ≤ 1.5 x ULN
- serum glutamate oxaloacetate transaminase (SGOT (AST) ≤2.5 x ULN
- serum glutamate pyruvate transaminase (SGPT (ALT) < 2.5 x ULN;
- Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to International Conference on Harmonization Good Clinical Practice (ICH GCP), and national/local regulations.Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- At least one measurable lesion that can be accurately assessed by CT/MRI/plain x-ray) at baseline and follow up visits.
Exclusion criteria:
- Systemic antitumor treatment within 21 days before study entry
- Simultaneous radiotherapy to the only target lesion
- Patients with resting ECG with QTc > 470 msec detected on 2 or more time points within a 24 hour period or family history of long QT syndrome. If ECG demonstrates QTc >470 msec, patient will be eligible only if repeat ECG demonstrates QTc ≤470 msec
- Patients who have experienced a seizure or seizures within 6 months of study treatment or who are currently being treated with cytochrome P450 enzyme inducing anti-epileptic drugs for seizures.
- Patients with uncontrolled brain metastases.
- Patients receiving prohibited classes of inhibitors of CYP3A4 (see section 6.5.1).
- Patients with gastrointestinal disorders likely to interfere with absorption of the study medication.
- Patients with any acute toxicities due to previous cancer treatment that have not resolved to a Common Toxicity Criteria for Adverse Effects (NCI-CTCAE v 4.03) grade 0 or 1 with the exception of chemotherapy induced alopecia and grade 2 peripheral neuropathy.
- Patients affected by myelodysplastic syndrome or acute myeloid leukemia
- Known to be serologically positive for HIV and receiving antiretroviral therapy
- Known seropositive for active viral infection with hepatitis B virus (HBV) (patients who are HBsAg negative, anti-HBs positive and/or hepatitis B core antigen (Anti-HBc) positive, but viral DNA negative are eligible)
- Known seropositive for active infection with hepatitis C virus (HCV)
- Patients unwilling or unable to comply with the protocol
- Patients with unstable angina pectoris, myocardial infarction ≤ 6 months prior to first study treatment, congestive heart failure New York Heart Association (NYHA) III-IV or serious uncontrolled cardiac arrhythmias
- Patients with an active or uncontrolled infection
- Patients who have a history of another primary malignancy and are off treatment for ≤ 3 years, with the exception of non-melanoma skin cancer
- Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above within 6 weeks
- Patients who have participated in another interventional clinical trial within 30 days before study entry
- Other serious medical conditions that could impair the ability of the patient to participate in the study
- Active infection requiring systemic antibiotic-, anti-viral-, or anti-fungal medication
- Active cancer (other than GCT) including prior malignancy from which the patient has been disease-free for ≤3 years (except superficial basal cell skin cancer)
- Patients with a known hypersensitivity to the combination/comparator agent
- Patients with uncontrolled seizures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Olaparib
Olaparib 300mg twice daily continuously
|
Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 30 months
|
The percentage of patients whose cancer achieve either a partial response or a complete response.Tumor response will be assessed using CT scan or MRI of chest/abdomen using the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and by tumor marker (AFP, betaHCG, LDH) measurements
|
Up to 30 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of number, type and grade of Adverse Events
Time Frame: Up to 30 months
|
All patients will be evaluable for toxicity from the time of their first treatment with Olaparib
|
Up to 30 months
|
Progression free survival (PFS)
Time Frame: Up to 30 months
|
time from the date of starting of the treatment to the date of the first observation of documented disease progression or death due to any cause.
Patients without tumor progression at the time of analysis will be censored at their last date of tumor evaluation.
|
Up to 30 months
|
Overall survival (OS)
Time Frame: Up to 30 months
|
Time from enrolment to the date of death due to any cause.
For subjects with no known date of death, survival time will be censored at the date of their last on-study assessment.
|
Up to 30 months
|
exploratory analysis of the association between PFS or OS and biomarkers
Time Frame: Up to 30 months
|
correlation between biomarkers (PAR, PARP-1, PTEN, XPA, ERCC1-3, XPF, FanD2, γ-H2AX) in paraffin-embedded tumor samples and plasma with clinical outcome (response, PFS, OS)
|
Up to 30 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Sandro Pignata, MD, Istituto Nazionale Tumori di Napoli
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRST186.02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms, Germ Cell and Embryonal
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; University of Southern... and other collaboratorsActive, not recruiting
-
National Cancer Institute, SlovakiaCompleted
-
Costantine AlbanyTesaro, Inc.WithdrawnGerm Cell Tumor
-
Hoosier Cancer Research NetworkMerck Sharp & Dohme LLCCompletedGerm Cell TumorsUnited States
-
Indiana University School of MedicineIndiana UniversityTerminatedGerm Cell TumorUnited States
-
University of SydneyDana-Farber Cancer Institute; University of Southern California; Cambridge University... and other collaboratorsRecruitingGerm Cell TumorAustralia, New Zealand, United States
-
Barts & The London NHS TrustUnknownGerm Cell TumourUnited Kingdom
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingGerm Cell TumorFrance
-
National Cancer Institute, SlovakiaCompleted
Clinical Trials on Olaparib
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingSmall Cell Lung Carcinoma | Small-cell Lung CancerUnited States
-
AstraZenecaMerck Sharp & Dohme LLC; Iqvia Pty LtdCompletedMalignant Solid TumorBelgium
-
CSPC Ouyi Pharmaceutical Co., Ltd.CompletedHealthy ParticipantsChina
-
Dana-Farber Cancer InstituteNovartis; AstraZenecaCompleted
-
Nordic Society of Gynaecological Oncology - Clinical...Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaboratorsRecruiting
-
AstraZenecaEuropean Network of Gynaecological Oncological Trial Groups (ENGOT)CompletedEpithelial Ovarian CancerDenmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
-
SandozCompleted
-
AstraZenecaMerck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaboratorsActive, not recruitingRelapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA MutatedKorea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
-
Qilu Pharmaceutical Co., Ltd.Completed
-
Leiden University Medical CenterUniversity Medical Center Groningen; Erasmus Medical CenterRecruitingBRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm EpithelialNetherlands